GlassScriptPhysician profile
Fouad Hachem
NPI 1316142813
$5,428.39
in general payments reported to CMS, 2019-2025
14 companies · $97.87 in 2025
The $97.87 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $40.92 · 2021: $855 · 2022: $3,295 · 2023: $34.92 · 2024: $166 · 2025: $97.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.14 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $3,968.39 | 2021-2024 | Echelon Flex |
| Covidien LP | $939.08 | 2019 | |
| Ethicon US, LLC | $138.13 | 2020-2025 | Echelon Flex, Echelon; Endopath, Linx Reflux Management System |
| Endogastric Solutions, INC | $120.20 | 2024 | Esophyx |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Novo Nordisk INC | $39.49 | 2021-2022 | |
| Medtronic, INC. | $37.73 | 2022 | |
| Smith+Nephew, INC. | $26.42 | 2020 | |
| Baxter Healthcare | $18.65 | 2023 | Floseal |
| Axonics, INC. | $17.80 | 2024 | Axonics |
| Heron Therapeutics, INC. | $16.27 | 2023 | Zynrelef |
| Merck Sharp & Dohme LLC | $14.53 | 2025 | Bridion |
| Avanos Medical | $11.94 | 2022 | |
| Tactile Systems Technology INC | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fouad Hachem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.